Related Experiment Video
Updated: Apr 12, 2026
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression
Roberta Mancuso1, Ambra Hernis2, Simone Agostini3
1Don C. Gnocchi Foundation - ONLUS, P.zza Morandi, 3, 20100, Milano, Italy. rmancuso@dongnocchi.it.
Background:
Demyelination and failure of remyelination are core mechanisms in the pathogenesis of multiple sclerosis (MS); the factor(s) modulating these processes are still mostly unknown. MicroRNA 572 (miR-572) is deregulated in MS and is suggested to targets neural cell adhesion molecule (NCAM), a glycoprotein involved in CNS reparative mechanisms. The aim of this study is to analyze miR-572 in patients with different clinical phenotypes of MS.
Methods:
qPCR quantification of miR-572 isolated from serum was performed in 16 primary progressive (PP), 15 secondary progressive (SP), 31 relapsing remitting (RR) MS patients and 15 sex-and age-matched healthy controls.
Results:
miR-572 expression was reduced overall in MS patients (p < 0.05) compared to HC; this miRNA was significantly upregulated in SPMS and in RRMS during disease relapse, whereas it was downregulated in PPMS and in quiescent phases of RRMS. miR-572 expression correlated with EDSS scores (RSp = 0.491; p < 0.05) independently of the clinical phenotype. The results suggest that this miRNA might be a tool that helps distinguishing between PPMS and SPMS and between relapsing and remitting phases in RRMS.
Conclusions:
Evaluation of miR-572 may serve as a non-invasive biomarker for remyelination.
Insights
MicroRNA 572 (miR-572) levels in multiple sclerosis (MS) patients vary by disease subtype and phase. This finding suggests miR-572 may serve as a non-invasive biomarker for remyelination processes in MS.
Area of Science:
- Neuroscience
- Molecular Biology
- Biomarker Discovery
Background:
- Multiple sclerosis (MS) pathogenesis involves demyelination and impaired remyelination, with underlying factors largely unknown.
- MicroRNA 572 (miR-572) is implicated in MS and may target neural cell adhesion molecule (NCAM), crucial for central nervous system repair.
- Investigating miR-572 in different MS clinical phenotypes is essential for understanding its role.
Purpose of the Study:
- To analyze the expression levels of miR-572 in patients with various clinical phenotypes of multiple sclerosis.
- To explore the potential of miR-572 as a biomarker for disease activity and remyelination in MS.
Main Methods:
- Quantitative real-time PCR (qPCR) was used to measure miR-572 levels in serum samples.
- Serum was collected from 16 primary progressive (PPMS), 15 secondary progressive (SPMS), 31 relapsing-remitting (RRMS) MS patients, and 15 healthy controls (HC).
Main Results:
- miR-572 expression was significantly reduced in MS patients compared to HC (p < 0.05).
- miR-572 was upregulated in SPMS and during relapsing phases of RRMS, but downregulated in PPMS and quiescent RRMS phases.
- miR-572 expression correlated with Expanded Disability Status Scale (EDSS) scores (RSp = 0.491; p < 0.05) across all phenotypes.
Conclusions:
- miR-572 levels may help differentiate between PPMS and SPMS, and between relapsing and remitting phases in RRMS.
- Evaluation of miR-572 shows potential as a non-invasive biomarker for assessing remyelination in multiple sclerosis.
More Related Videos
13:36Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation
Published on: July 23, 2012
10:37Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
